How does Congestive Heart Failure Alter Response to Drugs?

  • Dan M. Roden
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 75)


The process whereby administration of a drug results in pharmacologic effect depends on two major sets of variables: pharmacokinetic and pharmacodynamic factors. Pharmacokinetics refers to the relationship between dose of a drug and resultant drug concentrations (parent or metabolite; plasma or tissue). Methods to study the impact of variables such as age, disease state, or concomitant drug administration on plasma pharmacokinetics of drugs and metabolites have been fairly well worked out. It is convenient to think of pharmacodynamics as the relationship between drug concentration and effect. Although it is widely recognized that drug effects may vary among patients despite equivalent drug concentrations, methods for quantifying these pharmacodynamic differences are generally unavailable, so quantification of interindividual variability in drug “sensitivity” remains largely descriptive.


Congestive Heart Failure Adverse Drug Effect Intravenous Bolus Dose Pharmacokinetic Factor Therapeutic Margin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. 1.
    Woosley, R.L., Echt, D.S., and Roden, D.M.: Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am. J. Cardiol. 1986;57:25B–33B.PubMedCrossRefGoogle Scholar
  2. 2.
    Gomez, H.J., Grillo, V.J., and Irvin, J.D.: Enalapril: A review of human pharmacology. Drugs 1985;30:13–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Edelson, J., Stroshane, R., Benziger, D.P., Cody, R., Benotti, J., Hood, W.B., Jr., Chatterjee, K., Luczkowec, C., Krebs, C., and Schwartz, R.: Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 1986;73SIII:145–152.Google Scholar
  4. 4.
    Brater, D.C.: Disposition and response to bumetanide and furosemide. Am. J. Cardiol. 1986;57:20A–25A.PubMedCrossRefGoogle Scholar
  5. 5.
    Packer, M., and LeJemtel, T.H.: Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure. Prog. Cardiovasc. Dis. 1982;24:275–292.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • Dan M. Roden
    • 1
  1. 1.Vanderbilt University School of MedicineUSA

Personalised recommendations